Literature DB >> 27585993

Seizure control following treatment of brain arteriovenous malformations in pediatric patients.

Xiangke Ma1,2,3,4, Xianzeng Tong1,2,3,4, Jun Wu1,2,3,4, Yong Cao1,2,3,4, Shuo Wang5,6,7,8.   

Abstract

PURPOSE: Seizure outcome after treatment for pediatric patients with arteriovenous malformations (AVMs) has been rarely described in the literature. The aim of this study was to determine the risk factors for seizure presentation in pediatric AVM patients and the predictors for seizure control following treatment.
METHODS: We searched our characteristics of seizures associated with brain arteriovenous malformations prospectively maintained AVM database at Beijing Tiantan Hospital and identified 198 pediatric patients with brain AVMs between the year 2009 and 2014. Seizure presentation, patient characteristics, AVM features, treatment modalities, and postoperative outcomes, especially post-treatment seizure control were collected. Univariate and multivariate logistic regression analyses were applied to determine the risk factors for seizure presentation as well as the predictors for seizure control.
RESULTS: Before initiation of any treatments, 63 (31.8 %) of the overall 198 patients presented with seizure. According to multivariate analyses, larger AVM size, frontal AVM location, and history of prior hemorrhage were significantly associated with seizure presentation (all p < 0.05). For patients with pre-treatment seizure presentation, good seizure outcome was achieved in 73.8 %. AVM obliteration, short-period history of seizure, and short duration for seizure onset were independent predictors of good seizure outcome in the multivariate analysis. For the 135 patients without seizures at presentation, the overall rate of de novo seizures was 4.4 %.
CONCLUSION: In pediatric patients with brain AVMs, prior hemorrhage, larger AVM size, and frontal lobe location may predict subsequent seizures. Highest seizure control can be achieved by complete obliteration of the AVMs with microsurgical resection.

Entities:  

Keywords:  AVM size; Good seizure control; Obliteration rate; Risk factors

Mesh:

Year:  2016        PMID: 27585993     DOI: 10.1007/s00381-016-3216-x

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  36 in total

1.  Brain arteriovenous malformations in elderly patients: clinical features and treatment outcome.

Authors:  Xianzeng Tong; Jun Wu; Fuxin Lin; Yong Cao; Yuanli Zhao; Bo Ning; Bing Zhao; Lijun Wang; Shuo Zhang; Shuo Wang; Jizong Zhao
Journal:  Acta Neurochir (Wien)       Date:  2015-08-15       Impact factor: 2.216

2.  Comparison of pediatric and adult cerebral arteriovenous malformations.

Authors:  G D'Aliberti; G Talamonti; P P Versari; C Todaro; L Bizzozero; O Arena; M Collice
Journal:  J Neurosurg Sci       Date:  1997-12       Impact factor: 2.279

3.  Brain arteriovenous malformations and endovascular treatment: effect on seizures.

Authors:  X Lv; Y Li; C Jiiang; X Yang; Z Wu
Journal:  Interv Neuroradiol       Date:  2010-03-25       Impact factor: 1.610

4.  Radiosurgery for unruptured cerebral arteriovenous malformations: long-term seizure outcome.

Authors:  Seung-Yeob Yang; Dong Gyu Kim; Hyun-Tai Chung; Sun Ha Paek
Journal:  Neurology       Date:  2012-03-28       Impact factor: 9.910

5.  Postoperative seizure outcome in a series of 114 patients with supratentorial arteriovenous malformations.

Authors:  M L Thorpe; D J Cordato; M K Morgan; G K Herkes
Journal:  J Clin Neurosci       Date:  2000-03       Impact factor: 1.961

6.  Multimodality treatment of cerebral AVMs in children: a single-centre 20 years experience.

Authors:  Christian Dorfer; Thomas Czech; Gerhard Bavinzski; Klaus Kitz; Aygül Mert; Engelbert Knosp; Andreas Gruber
Journal:  Childs Nerv Syst       Date:  2009-11-28       Impact factor: 1.475

Review 7.  The psychiatric comorbidity of epilepsy.

Authors:  A Gaitatzis; M R Trimble; J W Sander
Journal:  Acta Neurol Scand       Date:  2004-10       Impact factor: 3.209

Review 8.  Treatment guidelines for cerebral arteriovenous malformation microsurgery.

Authors:  Robert M Starke; Ricardo J Komotar; Brian Y Hwang; Laura E Fischer; Matthew C Garrett; Marc L Otten; E Sander Connolly
Journal:  Br J Neurosurg       Date:  2009-08       Impact factor: 1.596

9.  Arteriovenous malformations of the brain: natural history in unoperated patients.

Authors:  P M Crawford; C R West; D W Chadwick; M D Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

10.  Results of multimodality treatment for 141 patients with brain arteriovenous malformations and seizures: factors associated with seizure incidence and seizure outcomes.

Authors:  Brian L Hoh; Paul H Chapman; Jay S Loeffler; Bob S Carter; Christopher S Ogilvy
Journal:  Neurosurgery       Date:  2002-08       Impact factor: 4.654

View more
  2 in total

1.  Children with Arteriovenous Malformations of the Central Nervous System: A Retrospective Study of 12 Pediatric Cases from a Single Tertiary Center in Slovenia.

Authors:  Ula Arkar; Tina Vipotnik Vesnaver; Anja Troha Gergeli; Neli Bizjak; Damjan Osredkar
Journal:  Med Sci Monit       Date:  2022-03-06

Review 2.  Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery.

Authors:  Shuli Liang; Xing Fan; Feng Chen; Yonghong Liu; Binghui Qiu; Kai Zhang; Songtao Qi; Guojun Zhang; Jinfang Liu; Jianguo Zhang; Jun Wang; Xiu Wang; Ziyang Song; Guoming Luan; Xuejun Yang; Rongcai Jiang; Hua Zhang; Lei Wang; Yongping You; Kai Shu; Xiaojie Lu; Guoyi Gao; Bo Zhang; Jian Zhou; Hai Jin; Kaiwei Han; Yiming Li; Junji Wei; Kun Yang; Gan You; Hongming Ji; Yuwu Jiang; Yi Wang; Zhiguo Lin; Yan Li; Xuewu Liu; Jie Hu; Junming Zhu; Wenling Li; Yongxin Wang; Dezhi Kang; Hua Feng; Tinghong Liu; Xin Chen; Yawen Pan; Zhixiong Liu; Gang Li; Yunqian Li; Ming Ge; Xianming Fu; Yuping Wang; Dong Zhou; Shichuo Li; Tao Jiang; Lijun Hou; Zhen Hong
Journal:  Ther Adv Neurol Disord       Date:  2022-08-16       Impact factor: 6.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.